A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma
Latest Information Update: 20 Aug 2024
At a glance
- Drugs Brentuximab vedotin (Primary) ; Bleomycin; Dacarbazine; Doxorubicin; Vinblastine
- Indications Hodgkin's disease
- Focus Registrational; Therapeutic Use
- Acronyms ECHELON-1
- Sponsors Seagen; Takeda Oncology
- 04 Jun 2024 Results demonstrating Seven-year overall survival analysis from ECHELON-1 study, presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 14 May 2024 According to a Takeda media release, data from this study will be presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 31-June 4, 2024, in Chicago, Ill.
- 18 Oct 2023 According to Takeda pharma media release, European Commission (EC) approved ADCETRIS (brentuximab vedotin) in combination with doxorubicin, vinblastine and dacarbazine AVD to treat adult patients with previously untreated CD30 Stage III Hodgkin lymphoma.